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ABSTRACT
Objective: To identify a cortical signature pattern of cortical thinning in familial Alzheimer disease
(FAD) and assess its utility in detecting and tracking presymptomatic neurodegeneration.
Methods: We recruited 43 FAD mutation carriers—36 PSEN1, 7 APP (20 symptomatic, 23 pre-
symptomatic)—and 42 healthy controls to a longitudinal clinical and MRI study. T1-weighted MRI
scans were acquired at baseline in all participants; 55 individuals (33 mutation carriers; 22
controls) had multiple (mean 2.9) follow-up scans approximately annually. Cortical thickness
was measured using FreeSurfer. A cortical thinning signature was identified from symptomatic
FAD participants. We then examined cortical thickness changes in this signature region in pre-
symptomatic carriers and assessed associations with cognitive performance.
Results: The cortical signature included 6 regions: entorhinal cortex, inferior parietal cortex, pre-
cuneus, superior parietal cortex, superior frontal cortex, and supramarginal gyrus. There were sig-
nificant differences in mean cortical signature thickness between mutation carriers and controls
3 years before predicted symptom onset. The earliest significant difference in a single region,
detectable 4 years preonset, was in the precuneus. Rate of change in cortical thickness became
significantly different in the cortical signature at 5 years before predicted onset, and in the pre-
cuneus at 8 years preonset. Baseline mean signature thickness predicted rate of subsequent thin-
ning and correlated with presymptomatic cognitive change.
Conclusions: The FAD cortical signature appears to be similar to that described for sporadic AD.
All component regions showed significant presymptomatic thinning. A composite signature may
provide more robust results than a single region and have utility as an outcome measure in pre-
symptomatic trials. Neurology® 2016;87:2050–2057
GLOSSARY
AD 5 Alzheimer disease; CDR 5 Clinical Dementia Rating; EYO 5 estimated years to symptom onset; FAD 5 familial
Alzheimer disease; MMSE 5 Mini-Mental State Examination; RMT 5 Recognition Memory Test; VOSP 5 Visual Object
and Space Perception battery.
There is great interest in testing potential disease-modifying treatments for Alzheimer disease
(AD) prior to the onset of symptoms.1,2 In order to facilitate this, robust and sensitive methods
are needed to identify at-risk individuals, stage their disease, and track progression.3,4
Studies of volumetric MRI, using automated cortical thickness measurement, have suggested
that sporadic AD is associated with cortical thinning in a relatively consistent pattern, or
“signature,” of cortical regions.5,6 A composite signature is likely to be more robust to interin-
dividual variation than using a single region alone. We were interested in seeing if a similar
cortical signature pattern of loss could be used to track changes presymptomatically in autosomal
dominant familial AD (FAD).
FAD shares many features, both pathologically and clinically, with the more common spo-
radic form of the disease.7 FAD genetic mutation carriers have relatively predictable ages at
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onset,8,9 which provides opportunity for pro-
spective longitudinal study of individuals prior
to the onset of clinical AD. Previous studies
identified reductions in brain volumes before
symptom onset, with longitudinal rates of
change appearing more sensitive than cross-
sectional measurement.10,11
We report the results of a prospective longi-
tudinal study of cortical thickness in FAD
mutation carriers. We first describe the identi-
fication of a cortical signature of FAD,
determined in symptomatic participants, and
then assess the utility of this approach in de-
tecting presymptomatic change, in terms of
both absolute thickness and rates of thinning.
We then assess if baseline thickness can predict
subsequent thinning and its correlation with
preclinical cognitive changes.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the local
research ethics committee and all participants provided written
informed consent.
Participants. We recruited 85 participants between 2009 and
2014 to an ongoing longitudinal study of FAD at the Dementia
Research Centre, University College London (appendix e-1 at
Neurology.org). Forty-three participants were carriers of
pathogenic mutations in either the presenilin 1 (PSEN1) (n 5
36) or amyloid precursor protein (APP) (n 5 7) genes and 42
were healthy controls (including 15 gene-negative siblings of the
mutation carriers). The mutation carrier group included a total of
14 different PSEN1mutations and 4 different APPmutations. At
baseline, 20 of the mutation carriers were symptomatic and 23
were presymptomatic.
There were 58 participants (43 mutation carriers and the 15
noncarrier siblings) from families affected by FAD, with 28 differ-
ent families represented. For these participants, genetic testing
was performed to determine the presence or absence of a muta-
tion. Genetic data were provided only to designated individuals
performing the statistical analysis, thus ensuring that both the
participants and the clinicians assessing them remained blind to
their genetic status.
At each timepoint, approximately annually, participants
underwent MRI, neurologic examination, detailed neuropsycho-
logical assessment, and assessment with the Mini-Mental State
Examination (MMSE) and Clinical Dementia Rating scale
(CDR). The neuropsychological test battery comprised measures
of general intellectual functioning (Wechsler Abbreviated Scale of
Intelligence); verbal and visual recognition memory (Recognition
Memory Test [RMT] for words and faces); short-term memory
(forward digit span); executive function (backwards digit span);
naming (Graded Naming Test); calculation (Graded Difficulty
Arithmetic Test); and visuoperceptual skills (object decision test
from the Visual Object and Space Perception battery [VOSP]).
All individuals identified a close informant who was interviewed
separately to gain a collateral history. Individuals were defined as
symptomatic if consistent symptoms of cognitive decline were re-
ported by the participant or their informant and the CDR was
.0. Estimated years to symptom onset (EYO) was calculated for
the presymptomatic mutation carriers by subtracting the partic-
ipant’s current age from the age at which the affected parent first
developed symptoms.
MRI acquisition. All participants at all timepoints were
scanned on the same 3T S TIM Trio scanner using a 32-
channel phased-array head coil. A sagittal 3D magnetization-
prepared rapid gradient echo T1-weighted volumetric MRI
(echo time/repetition time/inversion time 5 2.9/2,200/900 ms,
dimensions 256 3 256 3 208, voxel size 1.1 3 1.1 3 1.1 mm)
was acquired.
Image analysis. We measured cortical thickness across the cor-
tical mantle at approximately 300,000 vertices using FreeSurfer
v5.30’s (surfer.nmr.mgh.harvard.edu) cross-sectional pipeline.
Figure 1 The familial Alzheimer disease (FAD) cortical signature
(A) Results of FreeSurfer analysis indicate regions exhibiting the most significant cortical
thinning in the mildly symptomatic individuals with FAD from our cohort (p , 0.01, family-
wise error corrected). (B) The results of a literature search show regions previously high-
lighted as showing significant atrophy in FAD. We identified regions that were positive in
both the literature-driven and data-driven approaches, and included only these regions in our
final FAD cortical signature (C). A total of 6 regions were included: entorhinal cortex (red),
inferior parietal cortex (orange), precuneus (yellow), superior frontal cortex (green), superior
parietal cortex (purple), and supramarginal gyrus (blue).
Neurology 87 November 8, 2016 2051
The procedure used by FreeSurfer for the surface construction has
been described and validated previously.12,13 Two modifications
to the standard FreeSurfer processing stream were undertaken:
a locally generated brain mask was used for skull stripping and
ventricular segmentations were added to the white matter mask to
improve cortical segmentation. Cortical thickness was smoothed
with a 20-mm full-width at half-maximum kernel. All cortical
segmentations were visually inspected. Mean cortical thickness
values were calculated for 34 parcellated cortical regions
bilaterally.
Identifying the FAD cortical signature. We first undertook
a detailed literature review in PubMed, using the search terms
(familial Alzheimer disease) or (autosomal dominant Alzheimer
disease) and (cortical thickness) or (cortical volume), to iden-
tify the regions previously found to undergo significant cortical
atrophy in FAD (appendix e-1, table e-1). In addition, we sep-
arately analyzed data from our own cohort, using a conservative
statistical threshold (p , 0.001, family-wise error corrected),
to identify those regions that demonstrated the most
significant bilateral thinning in the baseline scans of the 10
mildest (according to MMSE) symptomatic participants
(appendix e-1). We then combined the results of these
literature-driven and data-driven approaches, and only
included regions in the final cortical signature that were
identified by both methods (figure 1).
Longitudinal mixed-effects modeling. We applied a longitu-
dinal linear mixed effects framework to model cortical thickness
in the signature regions using data from all mutation carriers
and noncarriers at all available timepoints (appendix e-1). The
model included fixed effects for age, sex, mutation carrier status,
and polynomial terms for EYO; a family level random effect for
intercept; and participant level random effects for intercept,
EYO, and mutation carrier status. Of the 85 participants, 55 in-
dividuals (33 mutation carriers and 22 controls) had scans at mul-
tiple longitudinal timepoints (mean 2.9, maximum 6; mean 6
SD interscan interval 5 448 6 172 days). This longitudinal
mixed effects approach was used to assess longitudinal change
in both absolute cortical thickness and rates of change in cortical
thickness.
In addition, we used linear mixed effects models to investigate
whether lower baseline thickness was associated with increased
rate of subsequent thinning, using data from the 33 mutation car-
riers who had scans at at least 2 timepoints. In this model, rate of
subsequent thinning was estimated by a fixed effect for duration
of follow-up. A fixed effect for interaction between baseline cor-
tical thickness and duration of follow-up estimated the strength of
association between the observed baseline value and rate of sub-
sequent thinning. The model included a fixed effect for sex, fam-
ily level random effect for intercept, and participant level random
effects for intercept and duration since baseline (appendix e-1).14
Assessing association between cortical signature change
and neuropsychological performance. To assess the clinical
implications of thinning within the cortical signature regions,
we analyzed associations between cortical thickness and perfor-
mance on neuropsychological testing in mutation carriers, both
before and after symptom onset. Spearman correlation coeffi-
cients were used to assess cross-sectional correlation between
mean cortical thickness across the 6 signature regions at
baseline and score on each focal neuropsychological test. In
addition, the following specific correlations were examined,
based on hypothesized associations between specific regions and
specific focal tests:
1. RMT (words and faces) and entorhinal cortex thickness.
2. Digit span forwards and superior frontal cortex, supramarginal
gyrus, and inferior parietal cortex thickness.
3. Digit span backwards and superior frontal cortex thickness.
4. Arithmetic and supramarginal gyrus and inferior parietal cor-
tex thickness.
5. VOSP object decision and supramarginal gyrus, inferior pari-
etal cortex, and superior parietal cortex thickness.
As well as examining the above correlations among all muta-
tion carriers, secondary analyses examined the correlation
between cortical thickness and neuropsychological test scores in
presymptomatic mutation carriers only. Cluster-adjusted (robust)
p values were used to account for clustering of individuals within
families. All analyses used STATA v13.0 or later.
RESULTS The cortical signature. Mutation carriers
and noncarriers were well-matched for age (43.2 years
[SD 9.4] vs 43.9 [9.4]) and sex (15 male/28 female vs
18 male/24 female). The group demographics, with
mutation carriers broken down into symptomatic and
presymptomatic, are shown in table 1.
Six cortical regions were identified as making up
the FAD cortical signature (figure 1): the entorhinal
cortex, the inferior parietal cortex, the precuneus, the
superior frontal cortex, the superior parietal cortex,
and the supramarginal gyrus.
Presymptomatic cortical thinning detectable across the
cortical signature. Our analysis of longitudinal cortical
thickness change found that, for all 6 cortical signa-
ture regions, there was strong evidence of a difference
in cortical thickness between mutation carriers and
controls (p , 0.0001 for all regions) and for a differ-
ence in rates of change in cortical thickness (p ,
0.0001 for all regions). Combining all signature re-
gions to give a mean signature measure showed cor-
tical signature thickness to be significantly lower in
mutation carriers compared to controls by 3 years
before predicted onset (figure 2, table 2). The earliest
significant difference in cortical thickness in any indi-
vidual region was detectable 4 years preonset, in the
precuneus.
Earlier differences between mutation carriers
and controls were apparent, for all 6 signature re-
gions, when comparing the rate of change in corti-
cal thickness, rather than the absolute cortical
thickness value alone (figure 2, table 2). Rates of
Table 1 Demographics and baseline clinical characteristics of the sample
Controls Presymptomatic Clinically affected
No. 42 23 20
Age, y (SD) 43.9 (9.4) 38.7 (7.8) 48.5 (8.8)
Sex, M/F 18/24 9/14 6/14
EYO, y (SD) — 7.5 (5.4) —
Global CDR (SD) 0 0 1.1 (0.43)
Abbreviations: CDR 5 clinical dementia rating scale; EYO 5 estimated years to onset.
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thinning in the mean signature summary measure
become nominally higher in mutation carriers com-
pared with controls at around 9 years before pre-
dicted onset, with the difference becoming
statistically significant by 5 years before predicted
onset. The earliest significant difference in rate of
change in an individual region was again observed
in the precuneus, with significant differences in
rates of thinning seen at 8 years preonset. A paired
t test, including all 6 signature regions, found the
change in rate to be significantly earlier than the
change in absolute thickness (p 5 0.005).
Across all mutation carriers, lower baseline corti-
cal thickness predicted greater thinning in the subse-
quent follow-up period. This association was
stronger for the mean signature summary measure
than for any region individually (table 2). A signif-
icant association remained between mean signature
thickness and future decline even when only
presymptomatic carriers were assessed (p 5 0.022);
a similar association was found in this group for the
precuneus (p 5 0.029).
Correlation between cortical signature thickness and
neuropsychological performance. Across all mutation
carriers, there were significant positive correlations
between the mean cortical signature summary mea-
sure and cognitive performance across tests of a wide
range of cognitive modalities (table 3). For each of
these tests, there was also significant correlation
between test performance and cortical thickness in
specific hypothesized individual cortical regions.
Looking at the presymptomatic participants only
(median time to onset 8 years), there remained a sta-
tistically significant correlation between cortical
thickness and performance in both verbal recognition
memory and arithmetic, but not with other domains
(table 3).
Figure 2 Longitudinal change in cortical thickness in the 6 cortical signature regions
Graphs compare mutation carriers and controls for (A) absolute cortical thickness value and (B) difference in rate of change in cortical thickness, with the
x-axes representing estimated time to/from onset of progressive cognitive symptoms. Graphs are shown for each cortical signature region as well as the
mean signature summary measure. Dotted lines indicate 95% confidence intervals.
Neurology 87 November 8, 2016 2053
Despite the precuneus not being one of our prehy-
pothesized regions for testing associations with cogni-
tive decline, as it had demonstrated the earliest
presymptomatic thinning of any individual region,
we undertook a post hoc analysis to assess its associa-
tion with presymptomatic cognitive performance. We
found that, in presymptomatic individuals, precuneus
thickness correlated with verbal recognition memory
only (Spearman R 5 0.48, p 5 0.018).
DISCUSSION We report results of longitudinal cor-
tical thickness change in presymptomatic FAD
within a disease-specific cortical signature. The
FAD cortical signature that we identified would
appear to closely resemble that previously
identified for sporadic AD,5 and included medial
parietal, lateral parietal, and medial temporal
regions. By then applying this cortical signature to
an independent group of presymptomatic mutation
carriers, we found that all 6 cortical signature regions
showed significant thinning a number of years
before the onset of cognitive symptoms.
Our findings suggest, consistent with previous
studies of FAD mutation carriers, that the precuneus
is one of the earliest regions to show significantly
reduced cortical thickness, at approximately 4 years
preonset.15,16 A previous cross-sectional study of
FAD, which applied the sporadic AD cortical signa-
ture (rather than a FAD-specific one), identified pre-
symptomatic thinning in 3 of the regions identified in
our study, including the precuneus, at an average of 6
years prior to onset.17 The reason for the slightly
earlier precuneus thinning in this study may have
been the increased homogeneity of the participants,
with all mutation carriers having the same mutation
(PSEN1 E280G).
Two other studies of presymptomatic FAD have
reported an initial increase in cortical thickness, prior
to later decline.18,19 The authors acknowledged that
this was unexpected, and speculated that it may indi-
cate a presymptomatic inflammatory process. Here,
in a larger sample, we find no evidence to support an
early cortical thickness rise. However, the possibility
that cortical thickness may increase in the earliest
presymptomatic phase—perhaps even earlier than
the period our study spanned—before falling as in-
dividuals come closer to symptom onset cannot be
excluded.
We found, across all 6 signature regions, that the
rate of change in cortical thickness allowed signifi-
cantly earlier detection of neurodegeneration than
a cross-sectional measure of thickness at a single time-
point (table 2). Previous imaging studies have simi-
larly suggested that rate of loss rather than absolute
volume/thickness may be more sensitive to early
pathologic change,10,11,16,20 although few FAD studies
have measured longitudinal change in cortical thick-
ness specifically. The timing of the increase in rate of
decline in cortical thickness from our study was
slightly earlier than found for other longitudinal vol-
umetric imaging measures.11,21
We found that, in mutation carriers, thickness
across the cortical signature regions correlated with
cognitive performance (table 3). This was true even
prior to the onset of symptomatic decline, in individ-
uals who were on average 8 years from predicted
Table 2 Longitudinal cortical thinning in the cortical signature regions
Cortical thickness
(MC vs NC), earliest
significant (p < 0.05)
difference (EYO)
Rate of change
(MC vs NC), earliest
significant (p < 0.05)
difference (EYO)
Association between baseline
cortical thickness and subsequent
rate of thinning (MC only)
Coefficient (mm/y
for every additional
mm at baseline) 95% CI p Value
Mean signature
summary measure
23 25 0.184 0.063 to 0.305 0.0028
Entorhinal cortex 22 25 0.115 20.104 to 0.335 0.30
Inferior parietal cortex 23 24 0.139 0.036 to 0.242 0.0080
Precuneus 24 28 0.105 0.029 to 0.180 0.0067
Superior frontal cortex 23 25 0.162 0.038 to 0.286 0.011
Superior parietal cortex 22 23 0.119 0.036 to 0.202 0.0049
Supramarginal cortex 22 25 0.081 0.009 to 0.152 0.027
Abbreviations: CI 5 confidence interval; EYO 5 estimated years to symptom onset.
A comparison between mutation carriers (MC) and noncarriers (NC), indicating the number of years prior to predicted
symptom onset when a significant difference is detectable in (1) cortical thickness and (2) the rate of change in cortical
thickness. All regions show significant presymptomatic thinning, including a mean signature measure. For all regions, apart
from the entorhinal cortex, there was a significant relationship between cortical thickness at a given timepoint and the
subsequent rate of thinning, with lower baseline thickness associated with a greater rate of subsequent decline. This
association was stronger for the mean cortical signature measure than for any individual region.
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symptom onset. In the presymptomatic mutation car-
riers, the closest correlation was between cortical
thickness and verbal episodic memory. This cognitive
domain has previously been identified as being the ear-
liest neuropsychological predictor of later decline.22–24
Compared to the precuneus—the cortical region that
showed the earliest thinning—the statistical significance
of the correlation between mean signature thickness
and verbal episodic memory was greater by an order
of magnitude.
Our findings also suggest that cortical signature
thickness at a given timepoint may have prognostic
value, in that it correlates significantly with future rate
of decline. When analyzing all mutation carriers, as-
sessing the mean thickness across a composite of pre-
selected cortical regions provided stronger prediction
of future decline than any single region alone (table
2), although when looking in presymptomatic indi-
viduals only the predictive value of the cortical signa-
ture and precuneus were similar. The finding that
a multiregion signature provides predictive power
and greater correlation with cognitive performance
than any region in isolation is consistent with the
concept that in AD there is early breakdown of a vul-
nerable but distributed neural network of different
interconnected regions; the variability between indi-
viduals in the patterns of loss and sequence of recruit-
ment of different regions with progression means that
a composite signature region may be a more robust
measure than a single region.25,26 A similar cortical
signature approach that we use here for FAD has
previously shown promise in identifying early symp-
tomatic sporadic AD.5,6,27
A composite cortical signature region may be useful
in the recruitment to, and monitoring of, presymp-
tomatic trials of disease-modifying therapies.2,3,7 The
use of a marker of AD neurodegeneration, such as the
cortical thickness signature, may allow presymptom-
atic disease staging by allowing prediction of how close
an individual is to symptom onset. A cortical signature
could also provide a means of quantifying loss over
time, a potentially valuable outcome biomarker.
Compared to previous imaging studies of FAD,
our study has a number of novel features that provide
important insights into presymptomatic disease. We
provide empiric evidence of the value of assessing
Table 3 Correlations between baseline cortical thickness and cognitive performance
Test Region
All mutation carriers
Presymptomatic carriers
only
Spearman R p Value Spearman R p Value
RMT faces Mean signature 0.41 0.005 0.077 0.74
Entorhinal 0.40 0.009 0.020 0.93
RMT words Mean signature 0.67 ,0.001 0.65 0.001
Entorhinal 0.50 0.001 0.57 0.001
Digit span forwards Mean signature 0.45 0.014 0.13 0.66
Superior frontal 0.45 0.013 0.19 0.41
Supramarginal 0.49 0.004 0.23 0.47
Inferior parietal 0.47 0.009 0.082 0.78
Digit span backwards Mean signature 0.60 ,0.001 0.29 0.32
Superior frontal 0.57 0.001 0.18 0.45
Arithmetic Mean signature 0.77 ,0.001 0.43 0.075
Supramarginal 0.78 ,0.001 0.51 0.027
Inferior parietal 0.70 ,0.001 0.28 0.27
VOSP Mean signature 0.28 0.053 0.18 0.42
Superior parietal 0.15 0.37 20.028 0.90
Inferior parietal 0.23 0.17 0.089 0.70
Supramarginal 0.23 0.095 0.18 0.30
Abbreviations: RMT 5 Recognition Memory Test; VOSP 5 Visual Object and Space Perception battery.
Spearman correlation coefficients are shown for performance on a number of focal cognitive tests and cortical thickness,
in mutation carriers only. Correlations were assessed between each cognitive test and the mean signature summary
measure, as well as for certain specific individual regions. To limit the number of comparisons, we constrained comparisons
between focal tests and individual regions to only those for which we had a priori hypotheses (based on the previous
literature). For each comparison, correlations were assessed both across the entire cohort and in presymptomatic
individuals only. A total of 39/43 mutation carriers were included: 17/20 affected and 22/23 presymptomatic (i.e., 3
affected and 1 presymptomatic participant had missing neuropsychology data).
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presymptomatic longitudinal rate of change in corti-
cal thickness, rather than just cross-sectional measure-
ment; of the potential predictive value of using
a composite signature region; and that cortical signa-
ture thickness is related to cognitive performance
even prior to symptom onset.
This study has a number of limitations. In the
selection of our cortical signature, we constrained
the regions to select from those that had been identi-
fied previously in the literature as involved in FAD.
While such an approach has the potential to introduce
bias, combining a priori information from the litera-
ture with an independent dataset can produce more
robust results, with greater face validity, when identi-
fying specific features of interest.28 In presymptomatic
mutation carriers, we used parental age at onset to
estimate the age at which an individual will develop
cognitive symptoms. While parental age at onset has
been shown to correlate closely with actual age at onset
and to closely relate to other methods of estimating
disease onset (e.g., based on family mean or mutation
mean age at onset), this remains a proxy measure,9 and
it is only with longer term follow-up that the actual
age at symptom onset can be confirmed.
A number of different genetic mutations were
included in our cohort, including mutations of both
the PSEN1 and APP genes. A degree of variability,
in terms of both clinical phenotype and radiologic
appearance, has been found between the different
FAD mutations, both between genes and within the
same gene,29,30 meaning that our cohort is likely to be
heterogeneous. While this diversity means it may be
more difficult to identify a common pattern, the
inclusion of different mutations and genes means that
the composite cortical signature identified is likely to
be more robust to interindividual variability. Future
validation of the utility of the cortical signature would
be valuable, ideally in a large cohort such as the Dom-
inantly Inherited Alzheimer’s Network.31 Also of
interest would be a direct comparison between thin-
ning patterns in familial and sporadic cases.
FAD is characterized by cortical thinning that is
detectable presymptomatically. Of the regions stud-
ied, the precuneus showed particularly early change.
However, a composite signature of multiple vulnera-
ble regions may provide more robust prediction of
future decline, and closer correlation with preclinical
cognitive change, than measuring a single region
alone. Rates of thinning in the cortical signature
became significantly abnormal about 2 years earlier
than absolute cortical thickness. This imaging mea-
sure may have utility in presymptomatic trials.
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